PNC-28

PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research[1][2].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

PNC-28 (0-0.5 mg/mL) blocks growth of a lethal human pancreatic cancer cell line[2]. Cell Proliferation Assay[2] Cell Line: MiaPaCa-2 human pancreatic carcinoma cells Concentration: 0.1, 0.3, and 0.5 mg/mL Incubation Time: daily Result: Showed dependent induction of tumor cell death starting at 0.1 mg/ml.

PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo[1]. PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor [1]. Animal Model: Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1] Dosage: 2 mg/mouse Administration: Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 μl/hr Result: No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor. Animal Model: Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)[1] Dosage: 1 mg/mouse, 10 mg/mouse and 20 mg/mouse Administration: When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days Result: Resulted in a significant level of tumor growth inhibition in a dose-related manner.